RGNT (NYSEAMERICAN:RGNT) Upgraded at ThinkEquity

RGNT (NYSEAMERICAN:RGNTGet Free Report) was upgraded by research analysts at ThinkEquity to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

RGNT Stock Performance

RGNT opened at $3.35 on Monday. RGNT has a fifty-two week low of $3.10 and a fifty-two week high of $8.35.

RGNT Company Profile

(Get Free Report)

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.

Read More

Receive News & Ratings for RGNT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RGNT and related companies with MarketBeat.com's FREE daily email newsletter.